This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Baek, S.J., Kim, J.S., Nixon, J.B., Di Augustine, R.P., and Eling, T.E. 2003. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR γ) ligand, selectively induces the early growth response-1 gene independently of PPAR γ J Biol Chem278: 5845–5853.
Brandon, M., Baldi, P., and Fallace, D.C. 2006. Mitochondrial mutations in cancer. Oncogene 25: 4647–4662.
Cadenas, E. 2004. Mitochondrial free radical production and cell signaling. Mol Aspects Med 25: 17–26.
Calderwood, S.K., Khaleque, M.A., Sawyer, D.B., and Ciocca, D.R. 2006. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem Sci 31: 164–172.
Capuano, F., Varone, D., D’Eri, N., Russo, E., Tommasi, S., Montemurro, S., Prete, F., and Papa, S. 1996. Oxidative phosphorylation and F0F1 ATP synthase activity of human hepatocellular carcinoma. Biochem Mol Biol Int 38: 1013–1022.
Carreras, M.C., Franco, M.C., Peralta, J.G., and Poderoso, J.J. 2004. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med 25: 125–139.
Cheng, W.C., Berman, S.B., Ivanovska,I., Jonas, E.A., Lee, S.J., Chen, Y., Kaczmarek, L.K., Pineda, F., and Hardwick, J.M. 2006. Mitochondrial factors with dual roles in death and survival. Oncogene 25: 4697–4705.
Clay, C.E., Monjazeb, A., Thorburn, J., Chilton, F.H., and High, K.P. 2002. 15-Deoxy-D12,14-prostaglandin J2-induced apoptosis does not require PPAR-γ in breast cancer cells J Lip Res43: 1818–1828.
Czarnecka, A.M., Campanella, C., Zummo, G., and Cappello, F. 2006. Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. Cancer Biol Ther 5: 714–720
Droge, W. 2002. Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95.
Fantin, V.R., St-Pierre, J., and Leder, P. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425–434.
Faure Vigny, H., Heddi, A., Giraud, S., Chautard, D., and Stepien, G. 1996. Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Mol Carcinog 16: 165–172.
Felty, Q., and Roy, D. 2005. Estrogen, mitochondria, and growth of cancer and non-cancer cells. J Carcinog 4: 1–18.
GaleE.A.2001. Lessons from the glitazones: A story of drug development. Lancet 357: 1870Ő1875.
Gatenby, R.A., and Gillies, R.J. 2004. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899.
Herrnstadt, C., Preston, G., and Howell, N. 2003. Errors, phantoms and otherwise, in human mtDNA sequences. Am J Hum Genet 72: 1585–1586.
Isley, W.L. 2003. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf: 2581–586.
Issemann, I., and Green, S. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650.
Kersten, S., Desvergne, B., and Wahli, W. 2000. Roles of PPARs in health disease. Nature 405: 421–424.
King, A., Selak, M.A., and Gottlieb, E. 2006. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 25: 4675–4682.
Krieg, R.C., Knuechel, R., Schiffmann, E., Liotta, L.A., Petricoin, E.F.III, and Herrmann, P.C. 2004. Mitochondrial proteome: Cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics 4: 2789–2795.
Mathupala, S.P., Ko, Y.H., and Pedersen, P.L. 2006. Hexokinase II: Cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777–4786.
McEnery, M.W., Hullihen, J., and Pedersen, P.L. 1989. F0 “proton channel” of rat liver mitochondria. Rapid purification of a functional complex and a study of its interaction with the unique probe diethylstilbestrol. J Biol Chem 264: 12029–12036.
Michalik, L., Desvergne, B., and Wahli, W. 2004. Peroxisome proliferator-activated receptor and cancers: complex stories. Nat Rev Cancer 4: 61–70.
Modica-Napolitano, J.S., and Singh, K.K. 2004. Mitochondrial dysfunction in cancer. Mitochondrion 4: 755–762.
Moncada, S., and Erusalimsky, J.D. 2002. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 3: 214–220.
Moreno-Sanchez, R., Rodriguez-Enriquez, S., Marin-Hernandez, A., and Saavedra, E. 2007. Energy metabolism in tumor cells. FEBS J 274: 1393–1418.
R.W., Nesto, D., Bell, R.O., Bonow, Fonseca, V., Grundy, S.M., Horton, E.S., Le Winter, M., Porte, D., Semenkovich, C.F., Smith, S., Young, and L.H., Kahn, R., 2004. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256–263.
Palakurthi, S.S., Aktas, H., Grubissich, L.M., Mortensen, R.M., and Halperin, J.A. 2001. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor g and mediated by inhibition of translation initiation. Cancer Res 61: 6213–6218.
Salas, A., Yao, Y.G., Macaulay, V., Vega, A., Carracedo, A., and Bandelt, H.J. 2005. A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2: 296.
Sanchez-Pino, M.J., Moreno, P., and Navarro, A. 2007. Mitochondrial dysfunction in human colorectal cancer progression. Front Biosci 12: 1190–1199.
Scatena, R., Nocca, G., Sole, P.D., Rumi, C., Puggioni, P., Remiddi, F., Bottoni, P., Ficarra, S., and Giardina, B. 1999. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 6: 781–787.
Scatena, R., Bottoni, P., Vincenzoni, F., Messana, I., Martorana, G.E., Nocca, G., De Sole, P., Maggiano, N., Castagnola, M., and Giardina, B. 2003. Bezafibrate induces a mitochondrial derangement in human cell lines: A PPAR-independent mechanism for a peroxisome proliferator. Chem Res Toxicol 16: 1440–1447.
Scatena, R., Bottoni, P., Martorana, G.E., Ferrari, F., De Sole, P., Rossi, C., and Giardina, B. 2004. Mitochondrial respiratory chain dysfunction, a non receptor-mediated effect of syntetic PPAR-ligands. Biochemical and pharmacological implications. Biochem Biophys Res Comm 319: 967–973.
Scatena, R., Bottoni, P., Martorana, G.E., Vincenzoni, F., Botta, G., Pastore, P., and Giardina, B. 2007. Mitochondria, ciglitazone and liver: A neglected interaction in biochemical pharmacology. Eur J Pharmacol 567: 50–58.
Takahashi, A., Ohtani, N., Yamakoshi, K., Iida, S., Tahara, H., Nakayama, K., Nakayama, K.I., Ide, T., Saya, H., and Hara, E. 2006. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8: 1291–1297.
Vinay, K., Abul, K., and Nelson, F. 2004. Neoplasia. In: Pathologic Basis of Disease (Robbins and Cotran, eds, pp. .)Elsevier Saunders:. Philadelphia, PA270–343.
Youssef, J., and Badr, M. 1998. Extraperoxisomal targets of peroxisome proliferators: Mitochondrial, microsomal, and cytosolic effects. Implications for health and disease. Crit Rev Toxicol 28: 1–33.
Zheng, J., and Ramirez, V.D. 1999. Purification and identification of an estrogen binding protein from rat brain: Oligomycin sensitivityconferring protein (OSCP), a subunit of mitochondrial F0F1-ATP synthase/ATPase. J Steroid Biochem Mol Biol 68: 65–75.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Scatena, R., Bottoni, P., Giardina, B. (2009). Mitochondrial Respiration and Differentiation. In: Mitochondria and Cancer. Springer, New York, NY. https://doi.org/10.1007/978-0-387-84835-8_6
Download citation
DOI: https://doi.org/10.1007/978-0-387-84835-8_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-84834-1
Online ISBN: 978-0-387-84835-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)